Form 4: Poplar Point Capital Partners LP Increases Stake in NovaBay Pharmaceuticals, Inc.

Poplar Point Capital Partners LP and related entities report increased holdings in NovaBay Pharmaceuticals through recent stock purchases.

Summary

• Poplar Point Capital Partners LP, along with Poplar Point Capital Management LLC, Poplar Point Capital GP LLC, and Jad Fakhry, jointly filed a Form 4.
• The filing reports changes in beneficial ownership of NovaBay Pharmaceuticals, Inc. (NBY) common stock.
• On January 27, 2025, Poplar Point Capital Partners LP acquired 31,703 shares at $0.69 per share, bringing their direct holdings to 550,000 shares.
• On January 31, 2025, they acquired an additional 70,685 shares at $0.6483 per share, increasing their direct holdings to 620,685 shares.
• The reporting persons include Poplar Point Capital Partners LP (PPCP), Poplar Point Capital Management LLC (PPCM), Poplar Point Capital GP LLC (PPCGP), and Jad Fakhry.
• PPCM is the investment manager of PPCP, PPCGP is the general partner of PPCP, and Mr. Fakhry is the manager of PPCM and PPCGP.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Increased investment by a major shareholder is generally a positive sign, but the filing itself is a routine disclosure.

Positives

• Increased investment by Poplar Point Capital Partners LP could signal confidence in NovaBay Pharmaceuticals' future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders and major shareholders. This filing indicates increased investment by a significant shareholder.

Stakeholder Impact

• Shareholders may view the increased stake by Poplar Point Capital Partners LP as a positive signal.

Key Dates

Keywords

NovaBay Pharmaceuticals, Poplar Point Capital Partners, Form 4, Beneficial Ownership, Stock Acquisition, NBY